About Perosphere Pharmaceuticals
Perosphere Pharmaceuticals is a company based in Danbury (United States) founded in 2011 was acquired by AMAG Pharma in December 2018. Perosphere Pharmaceuticals has raised $6.21 million across 1 funding round from investors including AMAG Pharma. Perosphere Pharmaceuticals operates in a competitive market with competitors including Freeline, Keros Therapeutics, Jasper Therapeutics, Disc Medicine and Interius Biotherapeutics, among others.
- Headquarter Danbury, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$6.21 M (USD)
in 1 rounds
-
Latest Funding Round
$6.21 M (USD), Series A
Feb 04, 2016
- Investors
-
Employee Count
Not available
-
Acquired by
AMAG Pharma
(Dec 13, 2018)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Perosphere Pharmaceuticals
Perosphere Pharmaceuticals has successfully raised a total of $6.21M through 1 strategic funding round. The most recent funding activity was a Series A round of $6.21 million completed in February 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Perosphere Pharmaceuticals
Perosphere Pharmaceuticals has secured backing from 1 investor. Prominent investors backing the company include AMAG Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Manufacturer of anemia based products and imaging agents for cancer and CVD diagnosis
|
Locked | Locked | Locked |
Investor details for Perosphere Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Perosphere Pharmaceuticals
Investment portfolio details for Perosphere Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Perosphere Pharmaceuticals
Detailed financials for Perosphere Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Perosphere Pharmaceuticals Comparisons
Peer comparison for Perosphere Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Perosphere Pharmaceuticals
Perosphere Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Freeline, Keros Therapeutics, Jasper Therapeutics, Disc Medicine and Interius Biotherapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Gene therapy platform is developed for chronic disease treatments.
|
|
| Locked | Locked | Locked |
Small molecules are developed to treat hematologic and musculoskeletal disorders.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for chronic diseases by targeting mast cells and stem cells
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of hematologic diseases
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating multiple diseases
|
|
| Locked | Locked | Locked |
Human plasma-based biopharmaceutical products are developed and commercialized.
|
Detailed competitors of Perosphere Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Perosphere Pharmaceuticals
Complete news archive for Perosphere Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Perosphere Pharmaceuticals
Perosphere Pharmaceuticals was founded in 2011 and raised its 1st funding round 5 years after it was founded.
Perosphere Pharmaceuticals is headquartered in Danbury, United States. It is registered at Danbury, Connecticut, United States.
Perosphere Pharmaceuticals is a funded company, having raised a total of $6.21M across 1 funding round to date.
Perosphere Pharmaceuticals is a specialty pharmaceutical company developing candidates that can re-establish normal blood coagulation in patients treated with anticoagulation drugs. Their lead candidate, ciraparantag (PER977) is a small synthetic water soluble NME which is intended for use as a reversal agent for the orally administered direct Factor Xa inhibitors and heparin is undergoing Phase 2 trials. The drug is being tested with anticoagulant products from Daiichi Sankyo, JJ, Bayer, BMS and Pfizer. The drug is FDA Fast Track designated. The company is also developing PER726, a drug targeting patients with status epilepticus (traumatic brain injury and are unresponsive to current therapies.
Perosphere Pharmaceuticals's top competitors include Keros Therapeutics, Disc Medicine and Freeline.
Perosphere Pharmaceuticals has 1 investor. Key investors include AMAG Pharma.